medroxyprogesterone injection / Generic mfg. - LARVOL DELTA

Idiopathic Intracranial Hypertension Prevalence and Hormonal Contraception: A Meta-Analysis. (PubMed, Neurology) - "The meta-analysis found no significant association between HC use and IIH prevalence, with consistent results across various HC modalities. This evidence provides confidence to reassure patients with IIH and clinicians that the directed use of HC should be continued as appropriate. The limited quality of available evidence and considerable heterogeneity highlights the necessity for large-scale, well-designed studies, particularly in diverse patient populations, to validate these findings."

Clinical • Journal • Retrospective data • Review • Cardiovascular • CNS Disorders • Hypertension • Long-acting Reversible Contraceptives • Women's Health

FEMUS: Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (clinicaltrials.gov) - P2/3 | N=260 | Recruiting | Sponsor: Fudan University | Not yet recruiting ➔ Recruiting

dMMR • Enrollment open • MSI-H • Tumor mutational burden • Endometrial Cancer • Oncology • Solid Tumor • ER • MSI • PD-L1 • POLE

Assessment of the risk of venous thromboembolism of combined hormonal contraceptives or progestin-only contraceptives in women over 18 in comparison with non-users or any other contraceptive (ISGE 2026) - "In contrast, progestin-only combinations had risks similar to non-use and were not statistically different, except for the medroxyprogesterone acetate injectable formulation, which showed an increased risk... A total of 85 studies were identified through abstract and full-text screening. Overall, 12 cohort and 17 case-control studies were included in the main quantitative analysis. Unadjusted analyses showed that, compared with non-use, all ethinyl estradiol-based combinations were associated with a significantly higher risk of VTE, with ethinyl estradiol/desogestrel showing the greatest excess risk."

Clinical • Cardiovascular • Hematological Disorders • Venous Thromboembolism

Addressing Unintended Teen Pregnancy Through Reproductive Health Service Delivery by School Nurses and Physicians. (PubMed, J Sch Health) - "By supporting access to reproductive health care, CATCH contributed to contraceptive uptake and reduced pregnancies among NYC teens."

Journal • Long-acting Reversible Contraceptives

School-Based Health Centers and Use of Effective Contraception among Sexually Active Female Teens in NYC Public High Schools. (PubMed, J Urban Health) - "SBHC RHP access significantly increased the probability of primary use of moderately effective hormonal contraception (pill/patch/ring/Depo-Provera shot) and LARC at last sex by 12.9 and 1.9 percentage points, respectively. While these more effective methods are generally less accessible to teens, the provision of these methods within an SBHC setting can increase access and use."

Journal • Long-acting Reversible Contraceptives

Continuation of Subcutaneous and Intramuscular Depot Medroxyprogesterone Acetate in Post-abortion Patients (clinicaltrials.gov) - P4 | N=263 | Completed | Sponsor: Northwestern University | Recruiting ➔ Completed | N=653 ➔ 263

Enrollment change • Trial completion

These "Children Won't Become Women": Depo-Provera, Intellectual Disability, and the Indian Health Service. (PubMed, J Hist Med Allied Sci) - "Framing Depo-Provera as a form of care enabled it to be deployed as a form of control over these women's menstruation and their bodyminds. Editor's Note: This article received the American Association for the History of Medicine 2025 Shryock Medal, an award for an outstanding, unpublished essay by a single author graduate student on any topic in the history of medicine."

Journal • Developmental Disorders • Mental Retardation • Mood Disorders • Oncology • Psychiatry

These "Children Won't Become Women": Depo-Provera, Intellectual Disability, and the Indian Health Service1. (PubMed, J Hist Med Allied Sci) - "These perceived benefits explain why some physicians and administrators championed routine injections of Depo-Provera in institutional settings, despite public backlash and concerns about the drug's potential to cause cancer. Framing Depo-Provera as a form of care enabled it to be deployed as a form of control over these women's menstruation and their bodyminds."

Journal • Developmental Disorders • Mental Retardation • Mood Disorders • Oncology • Psychiatry

In brief: New warning for injectable medroxyprogesterone. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Characteristics and Preoperative Management of Adolescent Patients With Pathology-Confirmed Endometriosis: A Multi-Institutional Study. (PubMed, Obstet Gynecol Surv) - "These included hormonal menstrual suppression (70.8%), including combined hormonal contraception, medroxyprogesterone acetate injection, progestin-only oral medication, hormonal intrauterine devices, contraceptive implants, and gonadotropin-releasing hormone analogs...Physical exam findings were most often unremarkable except in cases of mullerian anomalies; therefore, the decision to perform a pelvic exam can be individualized. Future research should focus on increasing the consistency of data through prospective research, as well as increasing the sample size and including patients who do not have pathologic confirmation of endometriosis but have a suspicion of it."

Clinical • Journal • Retrospective data • Endometriosis • Gynecology • Long-acting Reversible Contraceptives • Musculoskeletal Diseases • Musculoskeletal Pain • Pain • Pediatrics • Psychiatry • Women's Health

Comparative Effectiveness of Levonorgestrel Implant and Depot Medroxyprogesterone Acetate Injectable for Women Living With HIV on Dolutegravir-Based Antiretroviral Therapy. (PubMed, Pharmacoepidemiol Drug Saf) - "For WWH on DTG-based ART who are seeking reversible contraception, the LNG implant is an effective contraceptive and has substantially higher effectiveness than provider-administered DMPA injectables."

Clinical • HEOR • Journal • Human Immunodeficiency Virus • Infectious Disease

FEMUS: Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (clinicaltrials.gov) - P2/3 | N=260 | Not yet recruiting | Sponsor: Fudan University

dMMR • MSI-H • New P2/3 trial • P53mut • Tumor mutational burden • Endometrial Cancer • Oncology • Solid Tumor • ER • MSI • PD-L1 • POLE

Injectable contraceptives differentially affect the hypothalamic-pituitary-gonadal axis and amenorrhea incidence†. (PubMed, Biol Reprod) - "The Women's Health Injectable Contraception and HIV trial randomised 521 women to intramuscular depot medroxyprogesterone acetate (DMPA-IM) or norethisterone enanthate (NET-EN) and showed similar decreased estradiol levels, but more amenorrhea for DMPA-IM users. HPO hormone profiles differ between DMPA-IM and NET-EN users and compared to pre- and post-menopausal women. Mechanisms affecting amenorrhea likely differ between contraceptives, with lower 25W LH/FSH being consistent with more amenorrhea for DMPA-IM."

Journal • Human Immunodeficiency Virus • Infectious Disease • Long-acting Reversible Contraceptives • Women's Health

A five-year cost-consequence analysis of extended-use etonogestrel implant versus other contraceptives. (PubMed, J Med Econ) - "A discrete Markov chain model with 5-year time horizon simulated pregnancy outcomes among 1,000 women 18-49 years initiating 1 of 8 hormonal contraceptive branded or generic oral contraception (OC; progestin only and combined), medroxyprogesterone acetate injection, etonogestrel/ethinyl estradiol vaginal ring, norelgestromin/ethinyl estradiol transdermal patch, 3- or ≥5-year levonorgestrel IUD, and the etonogestrel implant. The etonogestrel implant was the most cost-effective contraceptive option when modeled over a 5-year period, offering the fewest pregnancies and lowest associated healthcare costs. Policies and practices that support initiation and continuation of the etonogestrel implant can enhance both clinical outcomes and overall cost-effectiveness."

Journal • Long-acting Reversible Contraceptives

No change in key HIV target cell markers following initiation of three progestin-based hormonal contraception methods: findings from the CHIME study. (PubMed, Front Immunol) - "Depot medroxyprogesterone acetate (DMPA) injectable, etonogestrel subdermal implant (ENG-implant), and levonorgestrel intrauterine device (LNG-IUD) are effective, widely used female hormonal contraceptives (HC)...Our findings suggest that commonly used HC methods do not result in immunologic changes that increase HIV acquisition risk. However, HIV infection enhancement with post-HC CVL in vitro warrants further study."

Biomarker • IO biomarker • Journal • Human Immunodeficiency Virus • Infectious Disease • Long-acting Reversible Contraceptives • CCR5 • CD38 • CD69 • ITGAE • PTPRC

Success of menstrual suppression for patients with obstructive Mullerian anomalies. (PubMed, J Pediatr Adolesc Gynecol) - "Most patients initiated on menstrual suppression in this cohort took combined oral contraceptive pills. Many patients reported effective suppression on pills containing 30mcg EE COC. Almost half of patients reported poor pain control on the initial menstrual suppression method."

Journal • Pain

Trends and patterns of concurrent contraceptive use with antihypertensive treatment in women using real-word data: Veteran Affairs Corporate Data Warehouse (AHA 2025) - "Types of contraceptive medication include combined oral contraceptive pills (yaz, ortho tri-cyclen), progestin-only pills (emicronor), vaginal rings (NuvaRing), transdermal patch (Ortho Evra), and injection (Depo-Provera). The most prescribed antihypertensive medication were beta blockers (43.78%), followed by diuretics (39.91%), alpha blockers (32.80%) and ACEI/ARBs (30.79%, n=40,518). Despite the current guideline, very low concomitant use of contraceptives (12%) with ACEI/ARB was observed in the study. While ACEI/ARB is the least prescribed medication to treat hypertension for reproductive age women, its use has been steadily increasing over the past decade, while rates of concurrent contraceptive use has decreased placing women at an increased risk of teratogenic exposure during pregnancy. Future studies are warranted to investigate the cause and barriers of suboptimal concomitant contraceptive utilization with ACEI/ARBs and pregnancy outcomes, including low birth..."

Clinical • Cardiovascular • Hypertension

Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women. (PubMed, JAMA Oncol) - "Higher risk was associated with oral desogestrel-only formulations (HR, 1.18; 95% CI, 1.13-1.23) and oral desogestrel-combined formulations (HR, 1.19; 95% CI, 1.08-1.31), as well as implants containing etonogestrel, desogestrel's active metabolite (HR, 1.22; 95% CI, 1.11-1.35), compared to levonorgestrel-containing combined pills (HR, 1.09; 95% CI, 1.03-1.15) and levonorgestrel, 52 mg, intrauterine system (HR, 1.13; 95% CI, 1.09-1.18). No statistically significant increased risk was observed for medroxyprogesterone acetate injection, etonogestrel vaginal ring, or combined oral drospirenone, despite having many users. Findings of this cohort study highlight that breast cancer risk varies substantially by progestin content in hormonal contraceptives, providing valuable insights to support more informed contraceptive prescription."

Journal • Breast Cancer • Cervical Cancer • Gynecology • Infertility • Oncology • Ovarian Cancer • Sexual Disorders • Solid Tumor • Uterine Cancer

#DepoProvera, An analysis of the most popular TikTok videos about Medroxyprogesterone Acetate. (PubMed, Contraception) - "#DepoProvera TikTok videos often depict negative personal experiences shared by laypeople, influencing patient perceptions of this contraceptive method."

Journal

Hormonal contraceptives and the risk of meningioma: a Swedish register-based case-control study. (PubMed, Neuro Oncol) - "This large register-based case-control study show a strong association between injectable hormonal contraceptives containing medroxyprogesterone and meningioma risk. The results add to the growing body of evidence of an association between meningiomas and progestins in general and the strong, consistent associations suggest a causal role of injectable medroxyprogesterone in meningioma growth. Our results correspond to two additional cases of meningioma per 10 000 women exposed to medroxyprogesterone per year."

Journal • Brain Cancer • Long-acting Reversible Contraceptives • Meningioma • Oncology • Solid Tumor

Uptake of intrauterine contraception after medical management of first trimester incomplete abortion: A cross-sectional study in central Uganda. (PubMed, PLoS One) - "The uptake of IUDs among post abortion women was nearly 60% emphasizing the potential impacts of integrated contraceptive services in Post abortion care. The impact of comprehensive and updated training on post abortion contraceptive counselling, is vital on the uptake of IUDs. Regardless of sociodemographic status, women seeking post abortion care in Uganda should be provided with high-quality integrated services by trained providers offering a range of contraceptive methods. Such efforts may not only prevent unintended pregnancies but also improve health equity across the country."

Journal • Observational data • Long-acting Reversible Contraceptives

PLEURAL ENDOMETRIOSIS AND CATAMENIAL PNEUMOTHORAX: A CASE REPORT FROM TREATMENT TO FAMILY PLANNING (FIGO 2025) - "She was referred to a tertiary gynecology service for follow-up after starting injectable medroxyprogesterone for hormonal blockage... The reported case emphasizes the importance of discussing the diagnosis and follow-up of a rare situation with variable clinical presentation, which is pleural endometriosis. The main pillar of treatment is the hormonal blockage of ectopic endometrial tissue, with special care in patients with gestational desire and the risk of disease recurrence after suspending or changing the hormonal method."

Case report • Clinical • Endometriosis • Gynecology • Long-acting Reversible Contraceptives • Respiratory Diseases • Women's Health

PULMONARY THROMBOEMBOLISM AFTER CONCURRENT SELF-MEDICATED HORMONE THERAPY IN A HIV TRANSGENDER WOMAN (FIGO 2025) - "At the beginning of 2023, the patient also started taking, every ten days, a non-prescribed monthly injectable contraceptive containing estradiol valerate 5 mg and norethisterone enanthate 50 mg. In April 2023, the patient took a dose of injectable medroxyprogesterone... Self-medication is a sociocultural phenomenon that persists even when medical care is available. Expanding provision of medical follow-up, providing safer options for those at increased risk for thromboembolic events, addressing expectatives and satisfaction of the patients with their hormone therapy, health education and mental health care are measures that can reduce the exposure of this population to such risks."

Clinical • Cardiovascular • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Long-acting Reversible Contraceptives • Pulmonary Disease • Pulmonary Embolism

THE LIVED EXPERIENCE OF SELF-INJECTABLE CONTRACEPTIVE USE: PERSPECTIVES FROM WOMEN IN RURAL MALAWI (FIGO 2025) - "The illustrative stories include "Nabanda," a 28-year-old who, after experiencing side effects from Depo-Provera, embraced SI for its logistical ease and the opportunity to involve her partner in the self-care experience. The lived experiences of women using SI in Malawi provide insights into the impact it can have in rural communities and the importance of investing in HSAs, addressing stockouts, and harnessing social support to optimize implementation of this novel self-care technology."

Clinical • Long-acting Reversible Contraceptives

Reproductive health knowledge and contraceptive use in never pregnant systemic lupus erythematosus patients: A cross-sectional survey. (PubMed, Lupus) - "Compared to the past, the current use of male condoms and withdrawal has significantly decreased (76.92% to 62.64%, p = .007, and 47.25% to 37.36%, p = .020, respectively), and effective contraceptive methods (oral contraceptive pills and medroxyprogesterone acetate injections) also have significantly declined (19.78% to 2.20%, p < .001, and 8.79% to 4.40%, p = .046, respectively)...There was no difference in contraceptive methods used, frequency of sexual activity, and SLE disease activity between patients who did and did not live with their partners.ConclusionsKnowledge of reproductive health, particularly contraceptive use in SLE patients, remains suboptimum. Formal reproductive health counseling should be carried out in all SLE patients for better contraception planning."

Journal • Immunology • Inflammatory Arthritis • Long-acting Reversible Contraceptives • Lupus • Nephrology • Systemic Lupus Erythematosus